Get started
Author

José Ignacio Fernández-Velasco

Observed names: J. I. Fernández Velasco, Jose I Fernández-Velasco, Jose I. Fernandez-Velasco, Jose Ignacio Fernandez Velasco, Jose Ignacio Fernandez-Velasco, Jose Ignacio Fernández-Velasco, José I. Fernández-Velasco, José Ignacio Fernández Velasco, jose ignacio Fernández Velasco
Observed institutions: University of Basel, Universidad de Alcalá, Instituto de Salud Carlos III, Hospital Universitari Arnau de Vilanova, University Hospital of Basel, Spanish Multiple Sclerosis Network, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario de La Princesa, Comunidad de Madrid, Hospital Universitario de Fuenlabrada, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario Ramón y Cajal, University of Birmingham
ORCID: 0000-0001-9148-671X
Observed ORCID: 0000-0001-9148-671X
OpenAlex ID: A5049239248
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
2021 · José I. Fernández-Velasco, Jens Kuhle, et al. · Neurology Neuroimmunology & Neuroinflammation · 67
PDF
High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
2020 · Enric Monreal, Susana Sainz de la Maza, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 58
PDF
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis
2024 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · Brain · 50
PDF
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs
2023 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · JAMA Neurology · 50
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome
2021 · Enric Monreal, Susana Sainz de la Maza, et al. · Neurology Neuroimmunology & Neuroinflammation · 40
PDF
Acetate correlates with disability and immune response in multiple sclerosis
2020 · Silvia Pérez-Pérez, María Inmaculada Domínguez-Mozo, et al. · PeerJ · 40
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
2021 · Carmen Picón, Amalia Tejeda-Velarde, et al. · Frontiers in Immunology · 28
PDF
Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study
2019 · J. P. Cuello, M. L. Martínez Ginés, et al. · European Journal of Neurology · 26
The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19
2020 · for the COVID-HRC group, Enric Monreal, et al. · Journal of Clinical Immunology · 23
PDF
Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults
2024 · Alexander Rodero-Romero, Enric Monreal, et al. · International Journal of Molecular Sciences · 22
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability
2021 · Rocco Capuano, Irati Zubizarreta, et al. · Multiple Sclerosis Journal · 18
Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls
2021 · Maria Inmaculada Dominguez-Mozo, Silvia Perez-Perez, et al. · Cells · 18
PDF
Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis
2023 · Enric Monreal, José Ignacio Fernández-Velasco, et al. · Frontiers in Immunology · 17
PDF
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis
2025 · Manuel Comabella, Agustín Pappolla, et al. · Neurology Neuroimmunology & Neuroinflammation · 13
PDF
Short‐chain fatty acids during pregnancy in multiple sclerosis: A prospective cohort study
2021 · Juan Pablo Cuello, María Luisa Martínez Ginés, et al. · European Journal of Neurology · 13
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
2021 · Paulette Esperanza Walo-Delgado, Susana Sainz de la Maza, et al. · Scientific Reports · 13
PDF
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients
2024 · Raquel Sainz-Amo, Alexander Rodero-Romero, et al. · International Journal of Molecular Sciences · 12
PDF
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
2024 · Fernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, et al. · Frontiers in Immunology · 10
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
2024 · Raquel Sainz-Amo, Alexander Rodero Romero, et al. · Frontiers in Immunology · 10
PDF
Soluble CD27 is an intrathecal biomarker of T-cell-mediated lesion activity in multiple sclerosis
2024 · Maria T. Cencioni, Roberta Magliozzi, et al. · Journal of Neuroinflammation · 10
PDF
Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis
2020 · Juan Pablo Cuello, María Luisa Martínez Ginés, et al. · Journal of the Neurological Sciences · 9
Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials
2022 · Ina Mexhitaj, Noha Lim, et al. · Journal of Immunological Methods · 8
PDF
Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
2021 · Paulette Esperanza Walo-Delgado, Enric Monreal, et al. · Frontiers in Immunology · 7
PDF
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression
2024 · Maria Inmaculada Dominguez-Mozo, Victoria Galán, et al. · Frontiers in Immunology · 6
Oligoclonal M bands unveil occult inflammation in multiple sclerosis
2022 · Bonaventura Casanova, Jessica Castillo, et al. · Multiple Sclerosis and Related Disorders · 6
Works count: 47
Citation count: 597
H-index: 13
I10-index: 20
Year
Topic
Type